-
公开(公告)号:US20220065863A1
公开(公告)日:2022-03-03
申请号:US17476148
申请日:2021-09-15
IPC分类号: G01N33/574 , A61N5/10
摘要: Methods of treating with radiation therapy a subject having cancer, in which the method comprises administering radiation therapy to the subject. The subject does not have an increased risk of having an adverse reaction to radiation therapy. The subject has an increased risk of an adverse reaction to radiation therapy when the subject's level of each component in a component profile from a sample of the subject is altered as compared to the normal level of each component. The component profile may comprise a metabolite panel of geranyl pyrophosphate, glucose-1-phosphate, and 3-hydroxy-3-methylglutaryl-CoA; a lipid panel of LPA 18:0, LPA 16:0, LPC 20:2, CER 24:0, and LPI 16:1; or a combination of these panels. The component profile may also comprise a metabolite panel of metanephrine, tryptophan, xanthurenic acid, and pantothenate; a lipid panel of LPA 18:0, DAG 16:0/18:0, LPA 16:0, and DAG 18:1/18:1; or a combination of these panels.
-
公开(公告)号:US20210383935A1
公开(公告)日:2021-12-09
申请号:US17406598
申请日:2021-08-19
发明人: Howard Federoff , Ophir Frieder
摘要: A triage system that determines whether a user is likely to have contracted a disease based on sensor data received from a user device (e.g., a smartphone or activity tracker). Each symptom is identified by comparing sensor data to a predetermined baseline and comparing the difference to a predetermined symptom threshold. Because direct measurement of symptoms using the sensors available to the user may not be feasible or sufficiently accurate, the triage system also uses surrogates the identify certain symptoms. For example, a fever may be identified using heart data, a cough or shortness of breath may be identified by analyzing recorded sound, fatigue may be identified by analyzing the movement of the user device, and loss of smell or taste may be identified by recording sound and using speech detection algorithms to identify phrases in the recorded sound indicative of loss of smell or taste.
-
公开(公告)号:US11151167B2
公开(公告)日:2021-10-19
申请号:US16654725
申请日:2019-10-16
发明人: Ophir Frieder , Ida Mele , Raffaele Perego , Nicola Tonellotto
IPC分类号: G06F16/00 , G06F16/28 , G06F16/2452 , G06N20/00 , G06F40/30 , G06F16/953
摘要: Embodiments may provide a cache for query results that can adapt the cache-space utilization to the popularity of the various topics represented in the query stream. For example, a method for query processing may perform receiving a plurality of queries for data, determining at least one topic associated with each query, and requesting data responsive to each query from a data cache comprising a plurality of partitions, including at least a static cache partition, a dynamic cache partition, and a temporal cache partition, the temporal cache partition may store data based on a topic associated with the data, and may be further partitioned into a plurality of topic portions, each portion may store data relating to an associated topic, wherein the associated topic may be selected from among determined topics of queries received by the computer system, and the data cache may retrieve data for the queries from the computer system.
-
公开(公告)号:US20210244797A1
公开(公告)日:2021-08-12
申请号:US16979817
申请日:2019-03-12
发明人: Christopher Albanese , Aisha Naeem
IPC分类号: A61K38/22 , A61K31/475 , A61K31/704 , A61P35/00
摘要: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin β-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.
-
公开(公告)号:US20210205456A1
公开(公告)日:2021-07-08
申请号:US17168614
申请日:2021-02-05
发明人: Esther H. CHANG , SangSoo KIM , Antonina RAIT
摘要: The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors. In embodiments, the liposomes deliver temozolomide across the blood-brain barrier for treatment of primary or metastatic brain tumors. Additional cancers that can be treated with the liposomes include neuroendocrine tumors, melanoma, prostate, head and neck, ovarian, lung, liver, kidney, breast, urogenital, gastric, colorectal, cervical, vaginal, angiosarcoma, liposarcoma, rhabdomyosarcoma, choriocarcinoma, pancreatic, retinoblastoma and other types of cancer. In another embodiment the liposomes deliver melphalan for the treatment of multiple myeloma, other tumors of the blood or other solid tumors. In still other embodiments the liposomes can deliver other drugs such as pemetrexed or irinotecan for treatment of cancer or drugs including atropine for treatment of organophosphate poisoning.
-
公开(公告)号:US10984130B2
公开(公告)日:2021-04-20
申请号:US16197813
申请日:2018-11-21
IPC分类号: G06F21/00 , G06F21/62 , G06F16/9535 , G06F16/2455 , G06F16/2453
摘要: Technologies are provided for efficiently querying a database using a plurality of oblivious random-access memories (ORAMs) while providing differential privacy. Subsets of a set of database records can be stored in a plurality of ORAMs. The subsets of database records in the separate ORAMs can be concurrently accessed (for example, by a database query server). When a database query is received, a number of database records that match the query can be identified for each of the ORAMs. A differential privacy constraint can be used to determine an additional number of database records to be retrieved from each ORAM. The differential privacy constraint can specify an upper bound on the number of records to be retrieved from each ORAM to prevent (or reduce the risk of) information leakage. Once all of the identified records are retrieved from the plurality of ORAMs, the additional records can be discarded.
-
公开(公告)号:US10948441B2
公开(公告)日:2021-03-16
申请号:US15764811
申请日:2016-09-30
发明人: YuYe J. Tong , Eric G. Sorte
摘要: A system for carrying out electrochemical nuclear magnetic resonance spectroscopy (EC-NMR) is disclosed, along with methods of manufacturing the EC-NMR system, and methods of using the EC-NMR system to monitor electrochemical reactions. The system comprises interdigitated electrodes arranged in a cylindrically symmetric manner. The system allows for nuclear magnetic resonance spectroscopy to be carried out on a sample during electrolysis with minimal effect to its sensitivity.
-
公开(公告)号:US20210048431A1
公开(公告)日:2021-02-18
申请号:US16978464
申请日:2019-03-08
申请人: MESO SCALE TECHNOLOGIES, LLC. , GEORGETOWN UNIVERSITY , BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人: Jeff DEBAD , Joshua GATSON , Mark BURNS , Arianna BIESSO
摘要: The present invention relates to assays, methods, and kits to assess traumatic brain injury (TBI) in a subject. The present invention also relates to ultrasensitive assays for GFAP, tau, CKBB, IL-1β, IL-2, IL-6, IL-10, IL-22, IP-10, TNFα, TSLP, NFL, and/or NFH.
-
公开(公告)号:US10916331B2
公开(公告)日:2021-02-09
申请号:US15577719
申请日:2016-06-03
IPC分类号: G16B15/00 , G16B15/30 , G06F5/01 , G06F17/11 , G06F111/10
摘要: Described herein are methods of predicting drug-target interactions and methods of using the information for drug repurposing. The methods described herein combine different descriptors, including, for example, atom pair similarity, shape, topology and chemical signatures, physico-chemical functional descriptors, contact points of the ligand and the target protein, chemical similarity, and docking score.
-
公开(公告)号:US10890589B2
公开(公告)日:2021-01-12
申请号:US15313163
申请日:2015-05-27
发明人: Massimo S. Fiandaca , Mark E. Mapstone , Howard J. Federoff , Xiaogang Zhong , Amrita K. Cheema
IPC分类号: A61K38/00 , C12Q1/68 , G01N33/567 , G01N33/68 , G01N33/92
摘要: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
-
-
-
-
-
-
-
-
-